Literature DB >> 27015881

Mesenchymal Stromal Cells Induce Peculiar Alternatively Activated Macrophages Capable of Dampening Both Innate and Adaptive Immune Responses.

Laura Chiossone1, Romana Conte2, Grazia Maria Spaggiari3, Martina Serra1, Cristina Romei1, Francesca Bellora3, Flavio Becchetti1, Antonio Andaloro1, Lorenzo Moretta4, Cristina Bottino1,3.   

Abstract

Mesenchymal stromal cells (MSCs) support hematopoiesis and exert immunoregulatory activities. Here, we analyzed the functional outcome of the interactions between MSCs and monocytes/macrophages. We showed that MSCs supported the survival of monocytes that underwent differentiation into macrophages, in the presence of macrophage colony-stimulating factor. However, MSCs skewed their polarization toward a peculiar M2-like functional phenotype (M(MSC) ), through a prostaglandin E2-dependent mechanism. M(MSC) were characterized by high expression of scavenger receptors, increased phagocytic capacity, and high production of interleukin (IL)-10 and transforming growth factor-β. These cytokines contributed to the immunoregulatory properties of M(MSC) , which differed from those of typical IL-4-induced macrophages (M2). In particular, interacting with activated natural killer (NK) cells, M(MSC) inhibited both the expression of activating molecules such as NKp44, CD69, and CD25 and the production of IFNγ, while M2 affected only IFNγ production. Moreover, M(MSC) inhibited the proliferation of CD8(+) T cells in response to allogeneic stimuli and induced the expansion of regulatory T cells (Tregs). Toll-like receptor engagement reverted the phenotypic and functional features of M(MSC) to those of M1 immunostimulatory/proinflammatory macrophages. Overall our data show that MSCs induce the generation of a novel type of alternatively activated macrophages capable of suppressing both innate and adaptive immune responses. These findings may help to better understand the role of MSCs in healthy tissues and inflammatory diseases including cancer, and provide clues for novel therapeutic approaches. Stem Cells 2016;34:1909-1921.
© 2016 AlphaMed Press.

Entities:  

Keywords:  Macrophages; Mesenchymal stromal cells; NK cells; PGE2; T cells

Mesh:

Substances:

Year:  2016        PMID: 27015881     DOI: 10.1002/stem.2369

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  69 in total

1.  Immune dysfunctionality of replicative senescent mesenchymal stromal cells is corrected by IFNγ priming.

Authors:  Raghavan Chinnadurai; Devi Rajan; Spencer Ng; Kenneth McCullough; Dalia Arafat; Edmund K Waller; Larry J Anderson; Greg Gibson; Jacques Galipeau
Journal:  Blood Adv       Date:  2017-04-25

Review 2.  The influence of macrophages on mesenchymal stromal cell therapy: passive or aggressive agents?

Authors:  F Carty; B P Mahon; K English
Journal:  Clin Exp Immunol       Date:  2017-02-20       Impact factor: 4.330

3.  The Impact of Morphine on the Characteristics and Function Properties of Human Mesenchymal Stem Cells.

Authors:  Vladimir Holan; Kristina Cechova; Alena Zajicova; Jan Kossl; Barbora Hermankova; Pavla Bohacova; Michaela Hajkova; Magdalena Krulova; Petr Svoboda; Eliska Javorkova
Journal:  Stem Cell Rev Rep       Date:  2018-12       Impact factor: 5.739

Review 4.  Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology.

Authors:  Norberto Perico; Federica Casiraghi; Giuseppe Remuzzi
Journal:  J Am Soc Nephrol       Date:  2017-11-30       Impact factor: 10.121

5.  Human Mesenchymal Stem Cell-Educated Macrophages Are a Distinct High IL-6-Producing Subset that Confer Protection in Graft-versus-Host-Disease and Radiation Injury Models.

Authors:  Myriam N Bouchlaka; Andrea B Moffitt; Jaehyup Kim; John A Kink; Debra D Bloom; Cassandra Love; Sandeep Dave; Peiman Hematti; Christian M Capitini
Journal:  Biol Blood Marrow Transplant       Date:  2017-02-28       Impact factor: 5.742

6.  In a Phase 1a escalating clinical trial, autologous mesenchymal stem cell infusion for renovascular disease increases blood flow and the glomerular filtration rate while reducing inflammatory biomarkers and blood pressure.

Authors:  Abdelrhman Abumoawad; Ahmed Saad; Christopher M Ferguson; Alfonso Eirin; Sandra M Herrmann; LaTonya J Hickson; Busra B Goksu; Emily Bendel; Sanjay Misra; James Glockner; Allan B Dietz; Lilach O Lerman; Stephen C Textor
Journal:  Kidney Int       Date:  2019-12-13       Impact factor: 10.612

7.  Splenic macrophage phagocytosis of intravenously infused mesenchymal stromal cells attenuates tumor localization.

Authors:  Suheyla Hasgur; Laura Desbourdes; Theresa Relation; Kathleen M Overholt; Joseph R Stanek; Adam J Guess; Minjun Yu; Pratik Patel; Linda Roback; Massimo Dominici; Satoru Otsuru; Edwin M Horwitz
Journal:  Cytotherapy       Date:  2021-03-26       Impact factor: 5.414

8.  Nasal administration of mesenchymal stem cells reverses chemotherapy-induced peripheral neuropathy in mice.

Authors:  Nabila Boukelmoune; Geoffroy Laumet; Yongfu Tang; Jiacheng Ma; Itee Mahant; Susmita K Singh; Cora Nijboer; Manon Benders; Annemieke Kavelaars; Cobi J Heijnen
Journal:  Brain Behav Immun       Date:  2020-12-11       Impact factor: 7.217

Review 9.  MSCs and Inflammatory Cells Crosstalk in Regenerative Medicine: Concerted Actions for Optimized Resolution Driven by Energy Metabolism.

Authors:  Valerie Planat-Benard; Audrey Varin; Louis Casteilla
Journal:  Front Immunol       Date:  2021-04-30       Impact factor: 7.561

10.  Jaw Periosteum-Derived Mesenchymal Stem Cells Regulate THP-1-Derived Macrophage Polarization.

Authors:  Fang He; Felix Umrath; Siegmar Reinert; Dorothea Alexander
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.